Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

2.

From plant extract to molecular panacea: a commentary on Stone (1763) 'An account of the success of the bark of the willow in the cure of the agues'.

Wood JN.

Philos Trans R Soc Lond B Biol Sci. 2015 Apr 19;370(1666). pii: 20140317. doi: 10.1098/rstb.2014.0317. Review.

3.

Role of the prostaglandin E2 EP1 receptor in traumatic brain injury.

Glushakov AV, Fazal JA, Narumiya S, Doré S.

PLoS One. 2014 Nov 26;9(11):e113689. doi: 10.1371/journal.pone.0113689. eCollection 2014.

4.

Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review.

Koog YH, Lee JS, Wi H.

PLoS One. 2014 Nov 3;9(11):e111776. doi: 10.1371/journal.pone.0111776. eCollection 2014. Review.

5.
6.

A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record.

Bolland MJ, Grey A.

BMJ Open. 2014 Oct 7;4(10):e005787. doi: 10.1136/bmjopen-2014-005787. Review.

7.

A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Gagne JJ, Wang SV, Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):619-27. doi: 10.1002/pds.3616. Epub 2014 Apr 30.

8.

Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Herder M, Gibson E, Graham J, Lexchin J, Mintzes B.

CMAJ. 2014 May 13;186(8):E287-92. doi: 10.1503/cmaj.131850. Epub 2014 Mar 10. Review. No abstract available.

10.

Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury.

Glushakov AV, Robbins SW, Bracy CL, Narumiya S, Doré S.

J Neuroinflammation. 2013 Oct 30;10:132. doi: 10.1186/1742-2094-10-132.

11.

Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.

Enayetallah AE, Puppala D, Ziemek D, Fischer JE, Kantesaria S, Pletcher MT.

BMC Pharmacol Toxicol. 2013 Sep 6;14:46. doi: 10.1186/2050-6511-14-46.

12.
13.

Industry influence in evidence production.

Dunn AG, Bourgeois FT, Coiera E.

J Epidemiol Community Health. 2013 Jul;67(7):537-8. doi: 10.1136/jech-2013-202344. Epub 2013 Jan 30. No abstract available.

14.

Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?

de Lorgeril M, Salen P, Defaye P, Rabaeus M.

BMC Med. 2013 Jan 4;11:5. doi: 10.1186/1741-7015-11-5.

15.

Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.

Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, Dionisi M, Tarozzo G, Piomelli D, Cavalli A, De Vivo M.

J Med Chem. 2012 Oct 25;55(20):8807-26. doi: 10.1021/jm3011146. Epub 2012 Oct 8.

16.

FDA approval of obesity drugs: a difference in risk-benefit perceptions.

Morrato EH, Allison DB.

JAMA. 2012 Sep 19;308(11):1097-8. No abstract available.

17.

"Safe and effective when used as directed": the case of chronic use of opioid analgesics.

Ballantyne JC.

J Med Toxicol. 2012 Dec;8(4):417-23. doi: 10.1007/s13181-012-0257-8. Review.

18.

Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model.

Dunn AG, Braithwaite J, Gallego B, Day RO, Runciman W, Coiera E.

BMC Health Serv Res. 2012 Aug 10;12:248. doi: 10.1186/1472-6963-12-248.

19.

Participants' responsibilities in clinical research.

Resnik DB, Ness E.

J Med Ethics. 2012 Dec;38(12):746-50. doi: 10.1136/medethics-2011-100319. Epub 2012 Jul 19.

20.

Public welfare agenda or corporate research agenda?

Singh A, Singh S.

Mens Sana Monogr. 2005 Mar;3(1):41-80. doi: 10.4103/0973-1229.27878.

Items per page

Supplemental Content

Write to the Help Desk